Jafron Biomedical Co Ltd Working Capital to Net Assets Ratio
Jafron Biomedical Co Ltd working capital to net assets ratio. Jafron Biomedical Co Ltd (300529) has a Working Capital to Net Assets ratio of 42.4% as of June 2026. Working capital of CN¥1.47 Billion (current assets of CN¥2.79 Billion minus current liabilities of CN¥1.32 Billion) is measured against net assets of CN¥3.46 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Jafron Biomedical Co Ltd (2011–2025)
Working capital to net assets ratio of Jafron Biomedical Co Ltd from 2011 to 2025. This chart shows how Jafron Biomedical Co Ltd's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of June 2026, the ratio stands at 42.4%, reflecting working capital of CN¥1.47 Billion against net assets of CN¥3.46 Billion CNY. Explore 300529 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Jafron Biomedical Co Ltd Working Capital to Net Assets Ratio by Year (2011–2025)
Jafron Biomedical Co Ltd working capital to net assets ratio by year from 2011 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Jafron Biomedical Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Jafron Biomedical Co Ltd (300529) total assets.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 69.6% | CN¥2.42 Billion | CN¥3.47 Billion | CN¥2.92 Billion | CN¥502.10 Million | ▲ +9.1 pp |
| 2024 | 60.5% | CN¥2.02 Billion | CN¥3.33 Billion | CN¥2.78 Billion | CN¥766.79 Million | ▼ -18.3 pp |
| 2023 | 78.7% | CN¥2.48 Billion | CN¥3.15 Billion | CN¥3.31 Billion | CN¥829.42 Million | ▲ +7.0 pp |
| 2022 | 71.7% | CN¥2.58 Billion | CN¥3.59 Billion | CN¥3.29 Billion | CN¥717.18 Million | ▼ -7.1 pp |
| 2021 | 78.9% | CN¥2.67 Billion | CN¥3.38 Billion | CN¥3.06 Billion | CN¥386.26 Million | ▲ +20.5 pp |
| 2020 | 58.4% | CN¥1.66 Billion | CN¥2.83 Billion | CN¥1.99 Billion | CN¥330.82 Million | ▼ -1.3 pp |
| 2019 | 59.8% | CN¥1.30 Billion | CN¥2.17 Billion | CN¥1.56 Billion | CN¥262.63 Million | ▲ +0.2 pp |
| 2018 | 59.6% | CN¥1.03 Billion | CN¥1.72 Billion | CN¥1.31 Billion | CN¥278.90 Million | ▼ -9.4 pp |
| 2017 | 69.0% | CN¥960.82 Million | CN¥1.39 Billion | CN¥1.23 Billion | CN¥269.84 Million | ▼ -8.2 pp |
| 2016 | 77.3% | CN¥914.91 Million | CN¥1.18 Billion | CN¥999.20 Million | CN¥84.29 Million | ▲ +22.1 pp |
| 2015 | 55.1% | CN¥311.03 Million | CN¥564.06 Million | CN¥400.19 Million | CN¥89.16 Million | ▼ -1.7 pp |
| 2014 | 56.9% | CN¥257.30 Million | CN¥452.42 Million | CN¥310.92 Million | CN¥53.62 Million | ▼ -8.0 pp |
| 2013 | 64.9% | CN¥246.63 Million | CN¥380.12 Million | CN¥299.92 Million | CN¥53.29 Million | ▼ -9.9 pp |
| 2012 | 74.8% | CN¥217.62 Million | CN¥290.84 Million | CN¥254.58 Million | CN¥36.95 Million | ▼ -9.7 pp |
| 2011 | 84.6% | CN¥182.30 Million | CN¥215.57 Million | CN¥210.83 Million | CN¥28.53 Million | — |